Ticker Details
Altimmune, Inc. Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases.
IPO Date:	May 22, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$606.76M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.33 | 4.69%
Avg Daily Range (30 D):	$0.06 | 2.21%
Avg Daily Range (90 D):	$0.10 | 2.92%

Institutional Daily Volume
Avg Daily Volume:	2M
Avg Daily Volume (30 D):	3.4M
Avg Daily Volume (90 D):	3.48M

Trade Size
Avg Trade Size (Sh.):	166
Avg Trade Size (Sh.) (30 D):	193
Avg Trade Size (Sh.) (90 D):	212

Institutional Trades
Total Institutional Trades:	1,667
Avg Institutional Trade:	$1.69M
Avg Institutional Trade (30 D):	$2.3M
Avg Institutional Trade (90 D):	$1.66M
Avg Institutional Trade Volume:	.22M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.89M
Avg Closing Trade (30 D):	$2.5M
Avg Closing Trade (90 D):	$1.74M
Avg Closing Volume:	255.35K

News

Jun 8, 2026 @ 5:00 PM Alcohol Use Disorder Market Set to Expand at a 12.... Source: Delveinsight

May 28, 2026 @ 3:00 PM Pemvidutide Demonstrates Significant Metabolic Imp... Source: Altimmune, Inc.

Apr 27, 2026 @ 11:00 AM Altimmune Announces Closing of $225 Million Oversu... Source: Altimmune Inc

Apr 23, 2026 @ 3:25 AM Altimmune Announces Pricing of $225 Million Oversu... Source: Na

Mar 24, 2026 @ 3:05 PM Anti-Aging Protein Research Takes a Step Forward w... Source: Equity-Insider.Com

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.18	$-.26	$-1
Diluted EPS	$-.18	$-.26	$-1
Revenue	$M	$.03M	$.04M
Gross Profit
Net Income / Loss	$-22.56M	$-27.36M	$-88.09M
Operating Income / Loss	$-24.24M	$-28.89M	$-94.49M
Cost of Revenue
Net Cash Flow	$53.84M	$-17.48M	$6.83M
PE Ratio

Splits
Sep 14, 2018	1:30
May 05, 2017	1:10
May 04, 2017	1:10
Jul 25, 2007	1:50